ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 4, 2023 GMT

BOULDER, Colo.--(BUSINESS WIRE)--Jan 4, 2023--

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the J.P. Morgan 41 st Annual Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PT (12:45 pm ET).

The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in multiple clinical trials in individuals with Duchenne muscular dystrophy or Becker muscular dystrophy. The Company is also advancing EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20230104005249/en/

CONTACT: Investors & Media

Michael Carruthers

Chief Financial Officer

ir@edgewisetx.com

ADVERTISEMENT

KEYWORD: UNITED STATES NORTH AMERICA COLORADO

INDUSTRY KEYWORD: HEALTH COMMUNICATIONS GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY PUBLIC RELATIONS/INVESTOR RELATIONS

SOURCE: Edgewise Therapeutics

Copyright Business Wire 2023.

PUB: 01/04/2023 08:30 AM/DISC: 01/04/2023 08:31 AM

http://www.businesswire.com/news/home/20230104005249/en